Previous Article | Next Article 
Infection and Immunity, November 1999, p. 5683-5689, Vol. 67, No. 11
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Identification of Promiscuous Epitopes from the
Mycobacterial 65-Kilodalton Heat Shock Protein Recognized by Human
CD4+ T Cells of the Mycobacterium leprae
Memory Repertoire
Abu S.
Mustafa,1,*
Knut E. A.
Lundin,2
Robert H.
Meloen,3
Thomas M.
Shinnick,4 and
Fredrik
Oftung5
Department of Microbiology, Faculty of
Medicine, Kuwait University, Safat, Kuwait1;
Institute of Transplantation Immunology, The National Hospital,
N-0027 Oslo, Norway2; Institute for
Animal Science and Health (ID-DLO), 8200 AB Lelystad, The
Netherlands3; Division of AIDS, STD, and
TB Laboratory Research, Centers for Disease Control and Prevention,
Atlanta, Georgia 303334; and
Department of Vaccinology, National Institute of Public
Health, N-0462 Oslo, Norway5
Received 9 April 1999/Returned for modification 7 June
1999/Accepted 5 August 1999
 |
ABSTRACT |
By using a synthetic peptide approach, we mapped epitopes from the
mycobacterial 65-kDa heat shock protein (HSP65) recognized by human T
cells belonging to the Mycobacterium leprae memory repertoire. A panel of HSP65 reactive CD4+ T-cell lines and
clones were established from healthy donors 8 years after immunization
with heat-killed M. leprae and then tested for
proliferative reactivity against overlapping peptides comprising both
the M. leprae and Mycobacterium tuberculosis
HSP65 sequences. The results showed that the antigen-specific T-cell lines and clones established responded to 12 mycobacterial HSP65 peptides, of which 9 peptides represented epitopes crossreactive between the M. tuberculosis and M. leprae HSP65
(amino acids [aa] 61 to 75, 141 to 155, 151 to 165, 331 to 345, 371 to 385, 411 to 425, 431 to 445, 441 to 455, and 501 to 515) and 3 peptides (aa 343 to 355, 417 to 429, and 522 to 534) represented
M. leprae HSP65-specific epitopes. Major histocompatibility
complex restriction analysis showed that presentation of 9 of the 12 peptides to T cells were restricted by one of the 2 HLA-DR molecules
expressed from self HLA-DRB1 genes, whereas 3 peptides with
sequences completely identical between the M. leprae and
M. tuberculosis HSP65 were presented to T cells by multiple
HLA-DR molecules: peptide (aa 61 to 75) was presented by HLA-DR1, -DR2,
and -DR7, peptide (aa 141 to 155) was presented by HLA-DR2, -DR7, and
-DR53, whereas both HLA-DR2 and -DR4 (Dw4 and Dw14) were able to
present peptide (aa 501 to 515) to T cells. In addition, the T-cell
lines responding to these peptides in proliferation assays showed
cytotoxic activity against autologous monocytes/macrophages pulsed with
the same HSP65 peptides. In conclusion, we demonstrated that
promiscuous peptide epitopes from the mycobacterial HSP65 antigen can
serve as targets for cytotoxic CD4+ T cells which belong to
the human memory T-cell repertoire against M. leprae. The
results suggest that such epitopes might be used in the peptide-based
design of subunit vaccines against mycobacterial diseases.
 |
INTRODUCTION |
The mycobacterial 65-kDa heat shock
protein (HSP65) is among the antigens recognized by Mycobacterium
leprae- and Mycobacterium tuberculosis-reactive human
CD4+ T cells (10, 13, 15, 35, 42). Several lines
of evidences suggest that the HSP65 antigen is relevant to subunit
vaccine design against mycobacterial diseases: cellular immune
responses to HSP65 induced by whole mycobacteria lead to activation of
CD4+ Th1 cells with protective effector functions such as
gamma interferon (IFN-
) release and major histocompatibility complex
(MHC) class II-restricted cytotoxic activity against antigen pulsed
macrophages (6, 28, 38, 43, 46). HSP65 is presented to human
CD4+ T cells in association with multiple HLA-DR molecules
(28). Mycobacterial HSP65-reactive CD4+ T cells
are present in the memory T-cell repertoire induced by M. leprae immunization in humans (32). Finally,
immunization with the mycobacterial HSP65 antigen induced protection
against M. leprae and M. tuberculosis in mouse
models of infections (4, 54, 55). In addition, DNA
vaccination of mice with the M. tuberculosis HSP65 antigen
provided protection against challenge with M. tuberculosis
(60).
These earlier studies suggest that the mycobacterial HSP65 represents a
candidate antigen for subunit vaccine design. However, immunization
with the complete HSP65 molecule may lead to adverse effects such as
autoimmune responses and the induction of suppressor T cells (11,
37, 66, 67). An alternative strategy could be to identify and
select HSP65 epitopes that are presented to CD4+ Th1 cells
in association with multiple HLA class II molecules. Although, several
epitopes of the mycobacterial HSP65 recognized by human T cells have
previously been identified (2, 12, 14, 43, 47), their
application to diagnosis or vaccine design is hampered by a
stringent HLA-DR restriction requirement. These studies demonstrated
that all investigated HSP65 epitopes could only be recognized by T
cells in association with one of the two HLA-DR molecules expressed
from the self-HLA-DRB1 genes (2, 12, 43, 47).
By using synthetic peptides covering both the M. tuberculosis and M. leprae HSP65 sequences, we have in
this study identified three novel HSP65 epitopes, each presented to
CD4+ T cells in association with multiple HLA-DR molecules.
The finding that such promiscuous epitopes were targets for recognition
by M. leprae-induced memory T cells in humans suggests that
they are relevant to vaccine development.
 |
MATERIALS AND METHODS |
Antigens and peptides.
Armadillo-derived killed M. leprae preparations were kindly supplied by R. J. W. Rees from the World Health Organization (WHO)/Immunology of Leprosy
(IMMLEP) Bank. The recombinant M. leprae and M. tuberculosis HSP65 were kindly provided by J. D. A. van
Embden from the WHO/IMMLEP Bank. Two sets of peptides were used to
identify the epitopes recognized by the mycobacterial HSP65-reactive
T-cell lines. The first set comprised 50 peptides (P1 to P50) covering
the amino acid (aa) sequence of the M. tuberculosis HSP65
(43). These peptides were 15-mers and overlapped with 5 aa.
Another series of 20 peptides (P51 to P70; 13-mers), corresponding to
the parts of the M. leprae HSP65 sequence that differed from
the M. tuberculosis sequence by one or more amino acids,
were synthesized by the Pepscan method as described previously
(20).
Antigen-presenting cells (APC).
Heparinized venous blood was
obtained from the Mycobacterium bovis BCG- and M. leprae-vaccinated subjects (5) and from healthy
individuals of the staff of the National Hospital, Oslo, Norway.
Peripheral blood mononuclear cells (PBMC) were separated by flotation
of the blood on Lymphoprep gradients (Nycomed, Oslo, Norway)
(23). Autologous and allogeneic irradiated (2,400 rads) PBMC
from a panel of donors were used as APC in T-cell proliferation assays.
HLA typing of donors.
Donors for T-cell lines and APC were
HLA typed serologically by the immunomagnetic method (64).
Donors vaccinated with M. bovis BCG and M. leprae
were, in addition, typed for Dw4 and Dw14 subtypes of DR4 by using
alloreactive T-cell clones (52). All of the donors were HLA
class II typed genomically by the hybridization of sequence-specific
oligonucleotide probes to PCR-amplified DNA (51). Testing
for the presence of the HLA-DRB4*0101 allele (encoding HLA-DR53) was done genomically for selected individuals and the vaccinated subjects.
HSP65-specific T-cell lines and clones.
M. leprae
HSP65-reactive T-cell lines were established from the PBMC of five
healthy subjects 8 years after vaccination with killed M. leprae (28, 32). To establish the T-cell lines, 2 × 106 PBMC in 1 ml of complete medium (RPMI 1640 plus 10%
AB serum and 1% penicillin-streptomycin) were cultured with M. leprae (5 × 107 bacilli/ml) in the wells of
24-well Costar plates (Costar, Cambridge, Mass.). The plates were
incubated at 37°C in an atmosphere of 5% CO2 and 95%
air. After 6 days of incubation, 100 U of recombinant interleukin-2
(Amersham, Amersham, United Kingdom) was added to the cultures twice a
week for 4 weeks (17). To expand the mycobacterial HSP65-reactive T cells, the lines were restimulated with M. leprae HSP65 and autologous APC (15). Phenotypically,
the T-cell lines were >95% CD4+ and <5%
CD8+. M. leprae HSP65-specific T-cell clones
were obtained from the M. leprae-induced T-cell lines by the
limiting dilution technique (22, 26). Growing clones were
expanded according to the protocols described previously
(30). All of the T-cell clones established were
CD4+ and CD8
.
T-cell proliferation assays.
Antigen-induced proliferation
assays of T-cell lines and clones were performed as previously
described (25, 39). In brief, 104 T cells were
added to the wells of 96-well flat-bottom Costar plates together with
105 irradiated autologous or HLA-DR-typed allogeneic PBMC
as APC. M. leprae (5 × 107 bacteria/ml),
M. leprae HSP65 (10 µg/ml), and synthetic peptides (5 µg/ml) were added in triplicates. The total culture volume was
adjusted to 200 µl. After 72 h of incubation, the cultures were
pulsed with 0.045 MBq of [3H]thymidine (specific
activity, 185 × 103 MBq/mM), and the radioactivity
incorporated was determined by liquid scintillation counting
(24). Median counts per minute (cpm) from triplicates were
used to calculate stimulation index (SI), which is defined as cpm in
cultures with amount of antigen per cpm in cultures without antigen.
The proliferation of T cells in response to a given antigen was
considered positive when the SI was >5 (19, 45). Such
values in the tables are given in boldface.
Inhibition assays with monoclonal anti-HLA antibodies.
The
inhibition of antigen-induced T-cell proliferation was studied as
described previously (16, 20, 27, 40, 43, 44) with the
monoclonal antibodies W6/32 (anti-HLA class I) and L243 (anti-HLA-DR),
purchased from the American Type Culture Collection, as well as FN81
(anti-HLA-DQ), a gift from S. Funderud, Oslo, Norway. In brief, APC in
the wells of 96-well flat-bottom plates were preincubated with the
antibodies for 30 min at 37°C in an atmosphere of 5% CO2
and 95% air. After preincubation, antigen-induced proliferation of
T-cell lines/clones was assessed as described above. The results were
calculated in terms of percent inhibition, which is defined as follows:
percent inhibition = (1
[cpm in antigen-stimulated
culture in the presence of antibody/cpm in antigen-stimulated cultures
in absence of antibody]) × 100.
Cytotoxicity assays.
Cytotoxicity of T-cell lines against
antigen-pulsed monocytes/macrophages was assessed by the neutral red
release assay as previously described (20, 25, 30, 36, 40,
44). In brief, adherent monocytes/macrophages from
106 autologous irradiated PBMC in 24-well Costar plates
were pulsed with the mycobacterial antigens. The T-cell clones were
added to 105 cells/well. After 7 days of incubation at
37°C, the wells were washed to remove nonadherent T cells and the
macrophages were allowed to take up neutral red for 30 min. The dye
taken up by macrophages was released by adding 0.5 ml of 0.05 M acetic
acid in 50% ethanol. The results are expressed as the percent
cytotoxicity, which was calculated from spectrophotometric measurement
of optical density at 540 nm (OD540) according to the
following formula: percent cytotoxicity = ([OD540
control
OD540 experimental]/[OD540 control]) × 100, where the OD540 control = the
OD540 of cultures with adherent cells plus T cells and the
OD540 experimental = the OD540 of cultures
with adherent cells plus T cells plus antigen.
 |
RESULTS |
Identification of peptides recognized by mycobacterial
HSP65-reactive T-cell lines.
Five T-cell lines (TCL1, TCL2,
TCL3, TCL4, and TCL5) responding to the M. leprae HSP65 in
proliferation assays were established from PBMC of an equal number of
donors 8 years after vaccination with heat-killed M. leprae.
To map the T-cell epitopes recognized, all T-cell lines were tested for
proliferative responses against 50 synthetic peptides (P1 to P50)
covering the complete sequence of the M. tuberculosis HSP65
and 20 peptides (P51 to P70) covering the regions of the M. leprae HSP65 that contain one or more amino acid substitutions
compared to the M. tuberculosis HSP65 sequence (30). The results showed that eight peptides corresponding
to the M. tuberculosis HSP65 sequence (i.e., P7, aa 61 to
75; P13, aa 141 to 155; P14, aa 151 to 165; P29, aa 331 to 345; P34, aa 371 to 385; P38, aa 411 to 425; P40, aa 431 to 454; and P47, aa 501 to
515) stimulated one or more of the T-cell lines tested (Table
1). Among the stimulatory peptides, P29,
P34, P38, and P40 were recognized by T-cell lines from single donors,
and P7 and P47 stimulated T-cell lines from two donors, whereas the P14 and P13 were recognized by T-cell lines from three and four donors, respectively (Table 1). Among the 20 peptides corresponding to the
M. leprae HSP65 sequence, two peptides (P61, aa 343 to 355; P62, aa 417 to 429) were stimulatory for T-cell lines from one donor
each (Table 1).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Proliferation of the M. leprae HSP65-reactive
T-cell lines in response to M. tuberculosis and M. leprae HSP65 peptidesa
|
|
Identification of HLA molecules used in T-cell recognition of HSP65
and its synthetic peptides.
To determine the MHC-restriction of
the T-cell lines, inhibition assays were performed with well-defined
anti-HLA class I and class II antibodies by using M. leprae
HSP65 as the antigen and irradiated autologous adherent cells as APC.
The results showed that only anti-HLA-DR antibodies were able to
inhibit the antigen-specific responses of all T-cell lines and clones
in a dose-dependent manner (Fig. 1,
representative results are given for two T-cell lines and two T-cell
clones).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Inhibition of the proliferative response of T-cell lines
and clones in the presence of anti-HLA class I and class II monoclonal
antibodies. The T-cell lines and clones were established from the
M. leprae-vaccinated donors as described in Materials and
Methods. Two T-cell lines, one each from donor 2 (TCL2) (A) and donor 4 (TCL4) (B), and two T-cell clones, one each from donor 2 (C) and donor
4 (D) were stimulated with M. leprae HSP65 in the presence
of defined monoclonal antibodies to HLA class I and class II molecules
at the concentrations indicated. The percent inhibition (as defined in
Materials and Methods) of the proliferative response is given for
anti-HLA class I ( ), anti-HLA-DQ ( ), and anti-HLA-DR ( )
antibodies.
|
|
To identify the HLA-DR molecules capable of presenting individual
epitopes, each T-cell line was stimulated with the M. leprae HSP65 and the positive peptides in the presence of autologous and
allogeneic HLA-DR-typed APC. The T-cell lines TCL1 (Table 2), TCL2 (Table
3), TCL4 (Table
5), and
TCL5 (Table 6) responded to the M. leprae HSP65 in the presence of autologous and allogeneic APC
expressing any one of the two HLA-DR molecules encoded by the
self-HLA-DRB1 alleles. In contrast, the restriction pattern of TCL3 (Table 4) suggested that this
T-cell line recognized the M. leprae HSP65 in association
with HLA-DR53, which is encoded by the HLA-DRB4 gene.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Mapping of MHC restriction for proliferation of TCL2 in
response to M. leprae HSP65 and peptides P13, P14,
and P47a
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 5.
Mapping of MHC restriction for proliferation of TCL4 in
response to M. leprae HSP65 and peptides P7, P13, P14, P47,
and P62a
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 6.
Mapping of MHC restriction for proliferation of TCL5 in
response to M. leprae HSP65 and peptides P7, P13,
and P14a
|
|
HLA-DR restriction analysis of T-cell lines with individual peptides
showed that the peptides which stimulated T-cell lines from single
donors were presented by one of the two HLA-DR molecules encoded by the
self-HLA-DRB1 genes of the respective donors (data are shown
for three representative peptides P61 [Table 2], P62 [Table 5], and
P34 [Table 6]). Among the peptides recognized by more than one T-cell
line, the peptide P14 was recognized in association with HLA-DR2 by all
the three responding T-cell lines, i.e., TCL2 (Table 3), TCL4 (Table
5), and TCL5 (Table 6). Peptide P47, which was recognized by two T-cell
lines, was restricted by HLA-DR2 for TCL2 (Table 3) and only by
autologous APC for TCL4 (Table 5). Peptide P7 stimulating the T-cell
lines from two donors was recognized in association with HLA-DR7 by
TCL4 (Table 5) and with HLA-DR1 and HLA-DR2 by TCL5 (Table 6). Peptide P13, which stimulated T-cell lines from four donors, was recognized in
association with HLA-DR2 by TCL2 (Table 3) and TCL5 (Table 6), with
HLA-DR2 and HLA-DR7 by TCL4 (Table 5), and with HLA-DR53 by TCL3 (Table
4).
Cytotoxic activity of T-cell lines against monocytes/macrophages
pulsed with HSP65 peptides.
The T-cell lines responding to
peptides P7 and P13 in proliferation assays were also tested for
cytotoxic activity against autologous monocytes/macrophages pulsed with
these HSP peptides. In addition, a nonstimulatory peptide (P50) was
used as a negative control antigen. The results revealed that the
T-cell lines proliferating in response to a given peptide also showed
cytotoxic activity against target cells pulsed with the same peptides.
The T-cell lines TCL4 and TCL5 were able to lyse peptide P7 pulsed
autologous monocytes/macrophages, whereas the T-cell lines TCL2, TCL4,
and TCL5 lysed target T cells pulsed with peptide P13. None of the T-cell lines tested showed cytotoxic activity against autologous monocytes/macrophages pulsed with peptide P50 (Table
7).
Identification of peptides and MHC molecules used in recognition of
HSP65 peptides by T-cell clones.
In addition to T-cell lines, we
also established M. leprae-reactive T-cell clones from the
same five donors. Among the 140 M. leprae responding T-cell
clones established, 29 and 18 T-cell clones responded to M. leprae and M. tuberculosis HSP65, respectively. When
tested for proliferative responses against the M. leprae and
M. tuberculosis HSP65 peptides, the peptides P13 (aa 141 to 155), P14 (aa 151 to 165), P29 (aa 331 to 345), P41 (aa 441 to 455),
and P47 (aa 501 to 515) stimulated the M. leprae and
M. tuberculosis HSP65 cross-reactive T-cell clones, whereas
the peptides P61 (aa 343 to 355) and P69 (aa 522 to 534) stimulated the
M. leprae HSP65-specific T-cell clones (Table
8).
View this table:
[in this window]
[in a new window]
|
TABLE 8.
Identification and HLA restriction of mycobacterial HSP65
peptides recognized by M. leprae and M. tuberculosis HSP65-reactive CD4+ T-cell clones
|
|
Inhibition assays with monoclonal anti-HLA antibodies showed that the
HSP65 induced responses of all T-cell clones tested were inhibited by
anti-HLA-DR antibodies (Fig. 1). Furthermore, testing for proliferative
responses in the presence of autologous and allogeneic HLA-DR typed APC
showed that each of the positive HSP65 peptides were recognized by the
T-cell clones in association with only one of the two HLA-DR molecules
encoded by the self-HLA-DRB1 alleles (Table 8).
 |
DISCUSSION |
The purpose of this study was to identify HSP65 epitopes that
could serve as targets for M. leprae-induced memory T cells in humans. We have previously shown that intradermal immunization of
humans with heat-killed M. leprae induces activation of
CD4+ memory T cells of the IFN-
-producing Th1 phenotype
which exhibit cytotoxicity against antigen-pulsed macrophages (18,
21, 30, 32, 33, 43). All of these characteristics are associated with T-cell responses mediating protective immunity against
mycobacterial infections (9, 48, 50, 61, 65). HSP65 epitopes
recognized by CD4+ T cells from such donors may therefore
be useful for the design of peptide vaccines against both tuberculosis
and leprosy. In addition, species-specific epitopes may also replace
the currently used diagnostic reagents such as tuberculin and lepromin,
which both contain cross-reactive antigens (3, 56).
However, the application of individual T-cell epitopes to the
development of vaccines, as well as diagnostic reagents, faces the
problem of MHC restriction (16, 20, 27, 36, 40, 43, 47). A
prerequisite for any antigen or epitope to induce cellular immune
responses in an HLA heterogeneous human population is its presentation
to CD4+ T cells in association with multiple HLA class II
molecules. By using T-cell clones, we and others have previously
demonstrated that only HLA-DR molecules expressed from the
self-HLA-DRB1 genes of each donor tested could serve as
restriction elements for peptide defined T-cell epitopes from the HSP65
antigen (29, 41, 47). The HLA-DRB1 locus is
highly polymorphic and this, along with the fact that any defined DR
molecule is only expressed in a minority of individuals at the
population level (31, 51), suggests that such epitopes are
not relevant to medical applications. To map a broader range of HSP65
T-cell epitopes relevant to prophylactic purposes, we have in this work
established and screened both HSP65 responding T-cell lines and clones
from M. leprae-immunized subjects for peptide reactivity in
relation to MHC restriction.
The cumulative results obtained with T-cell lines and clones lead to
the identification of 12 peptides from the mycobacterial HSP65 sequence
which possess T-cell epitopes relevant to memory immune responses. A
majority of the peptides represented epitopes cross-reactive between
the M. tuberculosis and M. leprae HSP65 (aa 61 to
75, 141 to 155, 151 to 165, 331 to 345, 371 to 385, 411 to 425, 431 to
445, 441 to 455, and 501 to 515), and three peptides (aa 343 to 355, 417 to 429, and 522 to 534) represented M. leprae
HSP65-specific epitopes. In addition, MHC restriction analysis showed
that presentation of 9 of the 12 peptides to T cells were
restricted by one of the HLA-DR molecules expressed from
self-HLA-DRB1 genes, whereas 3 peptides were presented to T
cells by multiple HLA-DR molecules.
Among the 12 HSP65 peptides identified in this study, four peptides (aa
411 to 425, 343 to 355, 417 to 429, and 522 to 534) were from the
regions that differ between the M. leprae and M. tuberculosis HSP65 sequences by one or more amino acid (Table 9) (53). The peptide (aa 411 to 425) contains a single conservative substitution in the M. leprae HSP65 sequence (Table 9). However, this substitution did
not affect T-cell recognition, since the M. leprae
HSP65-induced T-cell line responded to the corresponding M. tuberculosis peptide (aa 411 to 425). In contrast, the other three
peptides (aa 343 to 355, 417 to 429, and 522 to 534) were recognized as
specific for the M. leprae HSP65 antigen. When compared to
the M. tuberculosis HSP65 sequence, the M. leprae
HSP65 peptides (aa 522 to 534, 417 to 429, and 343 to 355) showed
4-, 2-, and 1-aa substitutions, respectively (Table 9). Nonconservative
substitutions of at least 1 aa were present in each peptide leading to
M. leprae-specific T-cell recognition (Table 9). However,
due to the fact that each peptide was recognized by T cells only in
association with single serologically defined HLA-DR specificities,
their potential as diagnostic reagents in HLA-DR heterogeneous
populations will be limited.
View this table:
[in this window]
[in a new window]
|
TABLE 9.
Sequence alignment of the M. leprae HSP65
peptides recognized by T-cell clones which differ from the M. tuberculosis HSP65 sequence by one or more
amino acidsa
|
|
The M. leprae HSP65-specific epitope represented by peptide
P62 (aa 417 to 429) has previously been reported to be recognized by
HLA-DR2-restricted M. leprae-specific T-cell clones from a tuberculoid leprosy patient (2). In addition, it was shown that these T-cell clones cross-reacted with a homologous peptide derived from the third hypervariable region of the HLA-DR2 molecule sequence (2). Since HLA-DR2 is associated with tuberculoid leprosy in some populations, it was speculated whether T-cell responses
against this peptide could be associated with immunopathological immune
responses rather than protection (2). However, our present finding that the same peptide (aa 417 to 429) was recognized by M. leprae HSP65-specific T cells from a healthy donor in the
context of HLA-DR2 suggests that such responses not necessarily are
relevant to immunopathology.
Of the 12 HSP65 peptides recognized by the CD4+ T-cell
lines and clones, 8 were completely identical in M. tuberculosis and M. leprae (53). Five of
these peptides were presented to T cells in association with one of the
two HLA-DR molecules expressed from the self-HLA-DRB1 genes,
and three of them were presented in association with more than one
HLA-DR molecule. Among the peptides presented to T-cell lines in the
context of multiple HLA-DR molecules, peptide P7 (aa 61 to 75) was
presented by HLA-DR1, -DR2, and -DR7, whereas peptide P13 (aa 141 to
155) was presented by HLA-DR2, -DR7, and -DR53. Peptide P7 (aa 61 to
75) was not recognized by the T-cell clones, and peptide P13 (aa 141 to
155) was recognized by T-cell clones from a single donor in association
with HLA-DR7 (Table 8). The third peptide (aa 501 to 515) recognized in
association with more than one HLA-DR molecule was presented to T cells
in association with HLA-DR2 (Table 3) and HLA-DR4 (Table 8).
In addition to identification of promiscuous epitopes, we also analyzed
our data with respect to T-cell epitopes which may be recognized by
several donors. An HLA-DR3-restricted dominant T-cell epitope of the
mycobacterial HSP65 (aa 2 to 12) has previously been identified by
using T-cell lines from several HLA-DR3-positive leprosy patients
(63). In this study, two overlapping peptides (aa 141 to 155 and aa 151 to 165) with sequences identical between M. leprae and M. tuberculosis were recognized by T cells
from all the three HLA-DR2-positive donors. Thus, these peptides could be considered as dominant epitopes for presentation to T cells in
association with HLA-DR2 molecules. However, the HLA-DR2-restricted epitopes in P13 (aa 141 to 155) and P14 (aa 151 to 165) must
represent two different sequences because these two peptides overlap by only 5 aa, and the minimum length of a peptide for binding to HLA-DR
and presentation to T cells is 7 to 8 aa (20, 44, 62).
In contrast to the peptide P14 (aa 151 to 165), which was recognized
only in the context of HLA-DR2, peptide P13 (aa 141 to 155) was also
presented by HLA-DR7 and HLA-DR53 molecules. Different subsets of T
cells probably existed in the polyclonal T-cell lines that recognized
peptide P13 bound with HLA-DR2, -DR7, and -DR53. The binding of a given
peptide to different HLA-DR molecules can generate unique epitopes
recognized by specific T cells (8). This observation is
supported from the experiments in which we raised T-cell clones from a
T-cell line that responded to peptide P13 (aa 141 to 155) in
association with HLA-DR2 and -DR7. The two M. leprae HSP65
responding T-cell clones established from this donor responded to
peptide P13 only in the context of HLA-DR7 (Table 8). These results
support the suggestion that different subsets of T cells recognized
peptide P13 in the context of different HLA-DR molecules.
Our results show that at least three HSP65 peptides are recognized in
association with multiple HLA-DR molecules. Of special interest is
peptide P13 (aa 141 to 155), which was recognized in association with
HLA-DR2 and -DR7, as well as with HLA-DR53. HLA-DR53 is the
serologically defined product of the HLA-DRB4 gene and is
coexpressed with the HLA-DRB1 gene products HLA-DR4, -DR7,
and -DR9. T-cell epitopes presented by HLA-DR53 are of considerable importance with respect to prophylaxis due to its frequent expression (up to 80%) in populations where mycobacterial diseases are endemic (1). We have previously reported a peptide-defined T-cell
epitope from a 24.1-kDa secreted lipoprotein common to M. leprae and M. tuberculosis that is also restricted by
HLA-DR53 (20, 34, 45). Importantly, the CD4+
T-cell lines studied here also showed peptide-specific cytotoxic activity, a characteristic which is associated with the inhibition of
mycobacterial growth within autologous macrophages (57).
On the basis of MHC restriction, cytotoxic activity, and representation
among the targets of the M. leprae memory T-cell repertoire, we consider the promiscuous HSP65 T-cell epitopes identified here as relevant components to be included in experimental subunit vaccines.
A major problem with peptide-based vaccines could be the poor
immunogenicity in the absence of potent adjuvants. However, recent
advances in DNA cloning and expression technologies have shown that
peptides could be delivered in highly immunogenic form to the cellular
immune system in the absence of classical adjuvants (7, 58,
59). Another potential limitation of using mycobacterial HSP65 or
its peptides in a prophylactic vaccine against tuberculosis and leprosy
could be the danger of inducing autoimmunity due to homology with the
human HSP65 (11, 66, 67). Fortunately, none of the three
promiscuous peptides of the mycobacterial HSP65 (aa 61 to 75, 141 to
155, and 501 to 515) belong to the regions of greatest homology between
the mycobacterial and human HSP65 (49). In addition, these
peptides have not been shown to possess epitopes recognized by T cells
from patients with autoimmune diseases (49, 67).
 |
ACKNOWLEDGMENTS |
This study was supported by Kuwait University Research
Administration Grant M1 114 and the Kuwait Foundation for Advancement of Sciences Project KFAS 97-0705. The recombinant antigens were provided through the WHO/IMMLEP Bank.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait. Phone: 965-5312300, ext. 6505. Fax: 965-5318454. E-mail: abusalim{at}hsc.kuniv.edu.kw.
Editor:
R. N. Moore
 |
REFERENCES |
| 1.
|
Aizawa, M.
1986.
DRw53, p. 175.
In
M. Aizawa (ed.), HLA in Asia-Oceania. Hokkaido University Press, Sapporo, Japan.
|
| 2.
|
Anderson, D. C.,
W. C. A. van Schooten,
M. E. Barry,
A. A. M. Janson,
T. M. Buchanon, and R. R. P. de Vries.
1988.
A Mycobacterium leprae-specific human T-cell epitope cross-reactive with an HLA-DR2 peptide.
Science
242:259-261[Abstract/Free Full Text].
|
| 3.
|
Bloom, B. R.
1986.
Learning from leprosy: a perspective on immunology and the Third World.
J. Immunol.
137:i-x.
|
| 4.
|
Gelber, R. H.,
V. Mehra,
B. Bloom,
L. P. Murray,
P. Siu,
M. Tsang, and P. J. Brennan.
1994.
Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse foot pads.
Infect. Immun.
62:4250-4255[Abstract/Free Full Text].
|
| 5.
|
Gill, H. K.,
A. S. Mustafa, and T. Godal.
1986.
Induction of delayed type hypersensitivity in human volunteers immunized with a candidate leprosy vaccine consisting of killed Mycobacterium leprae.
Bull. W. H. O.
64:121-126[Medline].
|
| 6.
|
Haanen, J. B. A. G.,
R. D. W. Malefijt,
P. C. M. Res,
E. M. Kraakman,
T. H. M. Ottenhoff,
R. R. P. deVries, and H. Spits.
1991.
Selection of a human T helper type 1-like cell subset by mycobacteria.
J. Exp. Med.
174:583-592[Abstract/Free Full Text].
|
| 7.
|
Hetzel, C.,
R. Janssen,
S. J. Ely,
N. M. Kristensen,
K. Bunting,
J. B. Cooper,
J. R. Lamb,
D. B. Young, and J. E. Thole.
1998.
An epitope delivery system for use with recombinant mycobacteria.
Infect. Immun.
66:3643-3648[Abstract/Free Full Text].
|
| 8.
|
Jurcevic, S.,
P. J. Travers,
A. Hills,
J. N. Agrewala,
C. Moreno, and J. Ivanyi.
1998.
Distinct conformations of a peptide bound to HLA-DR1 or DRB5*0101 suggested by molecular modelling.
Int. Immunol.
8:1807-1814[Abstract/Free Full Text].
|
| 9.
|
Kaufmann, S. H. E.
1996.
The interplay between cytokines and T-cells in immunity to intracellular bacteria, p. 169-180.
In
A. S. Mustafa, R. J. Al-Attiyah, I. Nath, and T. D. Chugh (ed.), T-cell subsets and cytokines interplay in infectious diseases. Karger AG, Basel, Switzerland.
|
| 10.
|
Kaufmann, S. H. E.,
U. Vath,
J. E. R. Thole,
J. D. A. van Embden, and F. Emmrich.
1987.
Enumeration of T-cells reactive with M. tuberculosis organisms and specific for the recombinant mycobacterial 64 kilodalton protein.
Eur. J. Immunol.
17:351-357[Medline].
|
| 11.
|
Lamb, J. R.,
V. Bal,
P. Mendez-Samperio,
A. Mehlert,
A. So,
J. Rothbord,
S. Jindal,
R. A. Young, and D. B. Young.
1989.
Stress proteins may provide a link between the immune response to infection and autoimmunity.
Int. Immunol.
1:191-196[Abstract/Free Full Text].
|
| 12.
|
Lamb, J. R.,
J. Ivanyi,
A. D. M. Rees,
J. B. Rothbard,
K. Howland,
R. A. Young, and D. B. Young.
1987.
Mapping of T-cell epitopes using recombinant antigens and synthetic peptides.
EMBO J.
6:1245-1249[Medline].
|
| 13.
|
Munk, E. M.,
B. Schoel, and S. H. E. Kaufmann.
1988.
T-cell responses of normal individuals towards recombinant protein antigens of Mycobacterium tuberculosis.
Eur. J. Immunol.
18:1835-1838[Medline].
|
| 14.
|
Munk, M. E.,
T. M. Shinnik, and S. H. E. Kaufmann.
1990.
Epitopes of the mycobacterial heat shock protein for human T-cells comprise different structures.
Immunobiology
180:272-277[Medline].
|
| 15.
|
Mustafa, A. S.
1988.
Identification of T-cell activating recombinant antigens shared among three candidate antileprosy vaccines, killed M. leprae, M. bovis BCG and Mycobacterium w.
Int. J. Lepr.
50:265-273.
|
| 16.
|
Mustafa, A. S.
1995.
Isolation and characterization of the genes of pathogenic mycobacteria that express antigens for T-cell reactivity.
Nutrition
11(Suppl. 5):653-656[Medline].
|
| 17.
|
Mustafa, A. S.
1996.
Restoration of proliferative response to M. leprae antigens in lepromatous T-cells against candidate antileprosy vaccines.
Int. J. Lepr.
64:257-267.
|
| 18.
|
Mustafa, A. S.
1996.
Recombinant mycobacterial antigens/epitopes recognized by human T-cells, p. 201-211.
In
A. S. Mustafa, R. J. Al-Attiyah, I. Nath, and T. D. Chugh (ed.), T-cell subsets and cytokines interplay in infectious diseases. Karger AG, Basel, Switzerland.
|
| 19.
|
Mustafa, A. S.,
H. A. Amoudy,
H. G. Wiker,
A. T. Abal,
P. Ravn,
F. Oftung, and P. Andersen.
1998.
Comparison of antigen specific T-cell responses of tuberculosis patients using complex or single antigens of Mycobacterium tuberculosis.
Scand. J. Immunol.
48:535-543[Medline].
|
| 20.
|
Mustafa, A. S.,
A. Deggerdal,
K. E. A. Lundin,
R. M. Meloen,
T. M. Shinnick, and F. Oftung.
1994.
An HLA-DRw53-restricted T-cell epitope from a novel Mycobacterium leprae protein antigen important to the human memory T-cell repertoire against M. leprae.
Infect. Immun.
62:5595-5602[Abstract/Free Full Text].
|
| 21.
|
Mustafa, A. S.,
A. Deggerdal, and F. Oftung.
1991.
Identification of recombinant mycobacterial protein antigens as vaccine candidates.
Immunology (Life Sci. Adv.)
10:139-147.
|
| 22.
|
Mustafa, A. S.,
H. K. Gill,
A. Nerland,
W. J. Britton,
V. Mehra,
B. R. Bloom,
R. A. Young, and T. Godal.
1986.
Human T-cell clones recognize a major M. leprae protein antigen expressed in E. coli.
Nature
319:63-66[Medline].
|
| 23.
|
Mustafa, A. S., and T. Godal.
1983.
In vitro induction of human suppressor T-cells by mycobacterial antigens. BCG activated OKT4+ cells mediate suppression of antigen induced T-cell proliferation.
Clin. Exp. Immunol.
52:29-37[Medline].
|
| 24.
|
Mustafa, A. S., and T. Godal.
1985.
BCG induced suppressor T-cells: optimal conditions for in vitro induction and mode of action.
Clin. Exp. Immunol.
62:474-481[Medline].
|
| 25.
|
Mustafa, A. S., and T. Godal.
1987.
BCG induced CD4+ cytotoxic T-cells from BCG vaccinated healthy subjects: relation between cytotoxicity and suppression in vitro.
Clin. Exp. Immunol.
69:255-262[Medline].
|
| 26.
|
Mustafa, A. S.,
G. Kvalheim,
M. Degre, and T. Godal.
1986.
Mycobacterium bovis BCG-induced human T-cell clones from BCG vaccinated healthy subjects: antigen specificity and lymphokine production.
Infect. Immun.
53:491-497[Abstract/Free Full Text].
|
| 27.
|
Mustafa, A. S.,
K. E. A. Lundin,
R. H. Meloen,
T. M. Shinnick,
A. F. W. Coulson, and F. Oftung.
1996.
HLA-DR4 restricted T-cell epitopes from the mycobacterial 60,000 MW heat shock protein (hsp 60) do not map to the sequence homology regions with the human hsp 60.
Immunology
87:421-427[Medline].
|
| 28.
|
Mustafa, A. S.,
K. E. A. Lundin, and F. Oftung.
1993.
Human T-cells recognize mycobacterial heat shock proteins in the context of multiple HLA-DR molecules: studies with healthy subjects vaccinated with Mycobacterium bovis BCG and Mycobacterium leprae.
Infect. Immun.
61:5294-5301[Abstract/Free Full Text].
|
| 29.
|
Mustafa, A. S.,
K. E. A. Lundin, and F. Oftung.
1997.
Mapping of HLA-DR4 restricted T-cell epitopes from the mycobacterial HSP60 with synthetic peptides, p. 704-705.
In
D. Charron (ed.), Proceedings of the 12th International Histocompatibility Workshop and Conference, vol. II. EDK, Paris, France.
|
| 30.
|
Mustafa, A. S.,
K. E. A. Lundin, and F. Oftung.
1998.
Isolation of recombinant phage clones expressing mycobacterial T-cell antigens by screening a recombinant DNA library with human CD4+ Th1 clones.
FEMS Immunol. Med. Microbiol.
22:205-216[Medline].
|
| 31.
|
Mustafa, A. S.,
S. Nadeem, and H. A. Amoudy.
1996.
Identification of HLA-DR molecules most frequently expressed by peripheral blood mononuclear cells of healthy subjects responding to mycobacterial antigens.
Kuwait Med. J.
1996(Suppl.):323-327.
|
| 32.
|
Mustafa, A. S., and F. Oftung.
1993.
Long-lasting T-cell reactivity to Mycobacterium leprae antigens in human volunteers vaccinated with killed M. leprae.
Vaccine
11:1108-1112[Medline].
|
| 33.
|
Mustafa, A. S., and F. Oftung.
1997.
Identification of mycobacterial recombinant antigens recognized by human T-cells.
Med. Princ. Pract.
6:57-65.
|
| 34.
|
Mustafa, A. S.,
F. Oftung,
A. Deggerdal,
H. K. Gill,
R. A. Young, and T. Godal.
1988.
Gene isolation using human T lymphocyte probes. Isolation of a gene that expresses an epitope recognized by T-cells specific for Mycobacterium bovis BCG and pathogenic mycobacteria.
J. Immunol.
141:2729-2733[Abstract].
|
| 35.
|
Mustafa, A. S.,
F. Oftung,
H. K. Gill, and I. Natvig.
1986.
Characteristics of human T-cell clones from BCG and killed M. leprae vaccinated subjects and tuberculosis patients.
Lepr. Rev.
57(Suppl. 2):123-130.
|
| 36.
|
Mustafa, A. S., and E. Qvigstad.
1988.
HLA-DR restricted antigen induced proliferation and cytotoxicity mediated by CD4+ T-cell clones from subjects vaccinated with killed M. leprae.
Int. J. Lepr.
57:1-11.
|
| 37.
|
Mutis, T.,
Y. E. Cornelisse,
G. Datema,
P. J. van den Elsen,
T. H. M. Ottenhoff, and R. R. P. de Vries.
1994.
Definition of a human suppressor T-cell epitope.
Proc. Natl. Acad. Sci. USA
91:9456-9460[Abstract/Free Full Text].
|
| 38.
|
Mutis, T.,
Y. E. Cornelisse, and T. H. M. Ottenhoff.
1993.
Mycobacteria induce CD4+ T-cells that are cytotoxic and display Th1-like cytokine secretion profile: heterogeneity in cytotoxic activity and cytokine secretion levels.
Eur. J. Immunol.
23:2189-2195[Medline].
|
| 39.
|
Oftung, F.,
E. Borka, and A. S. Mustafa.
1998.
Mycobacterium tuberculosis reactive T-cell clones from naturally converted PPD-positive healthy subjects: recognition of the M. tuberculosis 16-kDa antigen.
FEMS Immunol. Med. Microbiol.
20:319-325[Medline].
|
| 40.
|
Oftung, F.,
A. Geluk,
K. E. A. Lundin,
R. H. Meloen,
J. E. R. Thole,
A. S. Mustafa, and T. H. M. Ottenhoff.
1994.
Mapping of multiple HLA-class II epitopes of the mycobacterial 70-kilodalton heat shock protein.
Infect. Immun.
62:5411-5418[Abstract/Free Full Text].
|
| 41.
|
Oftung, F.,
K. E. A. Lundin,
A. Geluk,
T. H. M. Ottenhoff,
T. M. Shinnick,
R. Meloen, and A. S. Mustafa.
1997.
Primary structure and MHC restriction of peptide defined T-cell epitopes from recombinantly expressed mycobacterial protein antigens.
Med. Princ. Pract.
6:66-73.
|
| 42.
|
Oftung, F.,
A. S. Mustafa,
R. Husson,
R. A. Young, and T. Godal.
1987.
Human T-cell clones recognize two abundant Mycobacterium tuberculosis protein antigen expressed in Escherichia coli.
J. Immunol.
138:927-931[Abstract].
|
| 43.
|
Oftung, F.,
A. S. Mustafa,
T. M. Shinnick,
R. A. Houghton,
G. Kvalheim,
M. Degre,
K. E. A. Lundin, and T. Godal.
1988.
Epitopes of the Mycobacterium tuberculosis 65-kilodalton protein antigen as recognized by human T-cells.
J. Immunol.
141:2749-2754[Abstract].
|
| 44.
|
Oftung, F.,
T. M. Shinnick,
A. S. Mustafa,
K. E. A. Lundin,
T. Godal, and A. H. Nerland.
1990.
Heterogeneity among human T-cell clones recognizing an HLA-DR4,Dw4-restricted epitope from the 18 kDa antigen of Mycobacterium leprae defined by synthetic peptides.
J. Immunol.
144:1478-1483[Abstract].
|
| 45.
|
Oftung, F.,
H. G. Wiker,
A. Deggerdal, and A. S. Mustafa.
1997.
A novel mycobacterial antigen relevant to cellular immunity belongs to a family of secreted lipoproteins.
Scand. J. Immunol.
46:445-451[Medline].
|
| 46.
|
Ottenhoff, T. H. M.,
B. K. Ab,
J. D. A. van Embden,
J. E. R. Thole, and R. Kiessling.
1988.
The recombinant heat shock protein of Mycobacterium bovis bacillus Calmette-Guerin/M. tuberculosis is a target molecule for CD4+ cytotoxic T lymphocytes that lyse human monocytes.
J. Exp. Med.
168:1947-1952[Abstract/Free Full Text].
|
| 47.
|
Ottenhoff, T. H. M.,
J. B. A. G. Haanen,
A. Geluk,
T. Mutis,
B. K. Ab,
J. E. R. Thole,
W. C. A. van Schooten,
P. J. van den Elsen, and R. R. P. de Vries.
1991.
Regulation of mycobacterial heat-shock protein reactive T-cells by HLA class II molecules: lessons from leprosy.
Immunol. Rev.
121:171-191[Medline].
|
| 48.
|
Ottenhoff, T. H. M.,
D. Kumararatne, and J. L. Casanova.
1998.
Novel immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria.
Immunol. Today
19:491-494[Medline].
|
| 49.
|
Quayle, A. J.,
K. B. Wilson,
S. G. Li,
J. Kjeldsen-Kragh,
F. Oftung,
T. Shinnick,
M. Sioud,
O. Forre,
J. D. Capra, and J. B. Natvig.
1992.
Peptide recognition, T cell receptor usage and HLA restriction elements of human heat-shock protein (hsp) 60 and mycobacterial 65-kDa hsp-reactive T cell clones from rheumatoid synovial fluid.
Eur. J. Immunol.
22:1315-1322[Medline].
|
| 50.
|
Ravn, P.,
H. Boesen,
B. K. Pedersen, and P. Andersen.
1997.
Human T-cell responses induced by vaccination with Mycobacterium bovis Bacillus Calmette-Guerin.
J. Immunol.
158:1949-1955[Abstract].
|
| 51.
|
Ronningen, K. S.,
A. Spurkland,
G. Markussen,
T. Iwe,
F. Vartdal, and E. Thorsby.
1990.
Distribution of HLA class II alleles among Norwegian Caucasians.
Hum. Immunol.
29:275-281[Medline].
|
| 52.
|
Sharrock, C.,
K. E. A. Lundin,
K. Zeir,
A. Zeevi,
M. Thomson,
T. Eirmann,
J. A. Hansen,
E. Mickelson, and N. Flomenberg.
1988.
T-cell recognition of HLA class II molecules DR4 and DQw3, p. 509-513.
In
B. Dupont (ed.), Immunobiology of HLA, vol. 1. Springer-Verlag, KG, Heidelberg, Germany.
|
| 53.
|
Shinnick, T. M.,
D. Sweetser,
J. Thole,
J. van Embden, and R. A. Young.
1987.
The etiologic agents of leprosy and tuberculosis share an immunoreactive protein antigen with the vaccine strain Mycobacterium bovis BCG.
Infect. Immun.
55:1932-1935[Abstract/Free Full Text].
|
| 54.
|
Silva, C. L., and D. B. Lowrie.
1994.
A single mycobacterial protein (HSP 65) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis.
Immunology
82:244-248[Medline].
|
| 55.
|
Silva, C. L.,
M. F. Silva,
R. C. L. R. Pietro, and D. B. Lowrie.
1994.
Protection against tuberculosis by passive transfer with T-cell clones recognizing mycobacterial heat-shock protein 65.
Immunology
83:341-346[Medline].
|
| 56.
|
Snider, D. E.
1982.
The tuberculin skin test.
Am. Rev. Respir. Dis.
125:108-118[Medline].
|
| 57.
|
Stenger, S.,
R. J. Mazzaccaro,
K. Uyemura,
S. Cho,
P. F. Barnes,
J. P. Rosat,
A. Sette,
M. B. Brenner,
S. A. Porcelli,
B. R. Bloom, and R. L. Modlin.
1997.
Differential effects of cytolytic T cell subsets on intracellular infection.
Science
276:1684-1687[Abstract/Free Full Text].
|
| 58.
|
Suzue, K., and R. A. Young.
1996.
Adjuvant-free HSP70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24.
J. Immunol.
156:873-879[Abstract].
|
| 59.
|
Suzue, K.,
X. Zhou,
H. N. Eisen, and R. A. Young.
1997.
Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway.
Proc. Natl. Acad. Sci. USA
94:13146-13151[Abstract/Free Full Text].
|
| 60.
|
Tascon, R. E.,
M. J. Colston,
S. Ragno,
E. Stavropoulos,
D. Gregoy, and D. B. Lowrie.
1996.
Vaccination against tuberculosis by DNA injection.
Nat. Med.
2:888-892[Medline].
|
| 61.
|
Tascon, R. E.,
E. Stavropoulos,
K. V. Lukacs, and M. J. Colston.
1998.
Protection against Mycobacterium tuberculosis infection by CD8+ T cells requires the production of gamma interferon.
Infect. Immun.
66:830-834[Abstract/Free Full Text].
|
| 62.
|
Van der Zee, R.,
W. van Eden,
R. H. Meloen,
A. Noordzij, and J. D. A. van Embden.
1989.
Efficient mapping and characterization of a T-cell epitope by simultaneous synthesis of multiple peptides.
Eur. J. Immunol.
19:43-47[Medline].
|
| 63.
|
Van Schooten, W. C. A.,
D. G. Elferink,
J. Van Embden,
D. C. Anderson, and R. R. P. de Vries.
1989.
DR-3 restricted T-cells from different HLA-DR3 positive individuals recognize the same peptide (amino acids 2-12) of the mycobacterial 65-kDa heat shock protein.
Eur. J. Immunol.
19:2075-2079[Medline].
|
| 64.
|
Vartdal, F.,
G. Gaudernack,
S. Funderud,
A. Bratlie,
T. Lea,
J. Ugelstad, and E. Thorsby.
1986.
HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation a fast and reliable technique.
Tissue Antigens
28:301-312[Medline].
|
| 65.
|
Xing, Z.,
J. Wang,
K. Croitoru, and J. Wakeham.
1998.
Protection by CD4 or CD8 T cells against pulmonary Mycobacterium bovis bacillus Calmette-Guerin infection.
Infect. Immun.
66:5537-5542[Abstract/Free Full Text].
|
| 66.
|
Young, R. A.
1990.
Stress proteins and immunology.
Annu. Rev. Immunol.
8:401-420[Medline].
|
| 67.
|
Zugel, U., and S. H. E. Kaufmann.
1999.
Role of heat shock proteins in protection from and pathogenesis of infectious diseases.
Clin. Microbiol. Rev.
12:19-39[Abstract/Free Full Text].
|
Infection and Immunity, November 1999, p. 5683-5689, Vol. 67, No. 11
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mustafa, A. S., Al-Attiyah, R., Hanif, S. N. M., Shaban, F. A.
(2008). Efficient Testing of Large Pools of Mycobacterium tuberculosis RD1 Peptides and Identification of Major Antigens and Immunodominant Peptides Recognized by Human Th1 Cells. CVI
15: 916-924
[Abstract]
[Full Text]
-
Qamra, R., Mande, S. C.
(2004). Crystal Structure of the 65-Kilodalton Heat Shock Protein, Chaperonin 60.2, of Mycobacterium tuberculosis. J. Bacteriol.
186: 8105-8113
[Abstract]
[Full Text]
-
Al-Attiyah, R., Shaban, F. A., Wiker, H. G., Oftung, F., Mustafa, A. S.
(2003). Synthetic Peptides Identify Promiscuous Human Th1 Cell Epitopes of the Secreted Mycobacterial Antigen MPB70. Infect. Immun.
71: 1953-1960
[Abstract]
[Full Text]
-
Vordermeier, M., Whelan, A. O., Hewinson, R. G.
(2003). Recognition of Mycobacterial Epitopes by T Cells across Mammalian Species and Use of a Program That Predicts Human HLA-DR Binding Peptides To Predict Bovine Epitopes. Infect. Immun.
71: 1980-1987
[Abstract]
[Full Text]
-
Dockrell, H. M., Brahmbhatt, S., Robertson, B. D., Britton, S., Fruth, U., Gebre, N., Hunegnaw, M., Hussain, R., Manandhar, R., Murillo, L., Pessolani, M. C. V., Roche, P., Salgado, J. L., Sampaio, E., Shahid, F., Thole, J. E. R., Young, D. B.
(2000). A Postgenomic Approach to Identification of Mycobacterium leprae-Specific Peptides as T-Cell Reagents. Infect. Immun.
68: 5846-5855
[Abstract]
[Full Text]
-
Mustafa, A. S., Shaban, F. A., Abal, A. T., Al-Attiyah, R., Wiker, H. G., Lundin, K. E. A., Oftung, F., Huygen, K.
(2000). Identification and HLA Restriction of Naturally Derived Th1-Cell Epitopes from the Secreted Mycobacterium tuberculosis Antigen 85B Recognized by Antigen-Specific Human CD4+ T-Cell Lines. Infect. Immun.
68: 3933-3940
[Abstract]
[Full Text]